Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation

Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation

For a simplified snapshot from TREAT Asia/amfAR on ledipasvir and sofosbuvir co-formulation for the treatment of hepatitis C, please click here.

/ News

Related Posts

The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
Strategies to Secure Access to Generic HCV Medicines
Four Indian generic companies take sub license from MPP on daclatasvir
Flawed patents on hepatitis C drugs latest to be challenged in global push for access
Support letter for inclusion of Daclatasvir on 4th March, 2015.
Pricing and availability of generic Indian daclatasvir as on 7 March 2016
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
New WHO guideline on care and treatment of chronic hepatitis C